Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

701. Randomized, Double-Blind, Placebo-Controlled Study of Paliperidone Extended-Release and Quetiapine in Inpatients With Recently Exacerbated Schizophrenia (Abstract)

Randomized, Double-Blind, Placebo-Controlled Study of Paliperidone Extended-Release and Quetiapine in Inpatients With Recently Exacerbated Schizophrenia The authors compared paliperidone extended-release and quetiapine in patients with recently exacerbated schizophrenia requiring hospitalization.In a 6-week double-blind study, inpatients with a recent exacerbation of schizophrenia were randomly assigned to treatment with paliperidone extended-release, quetiapine, or placebo. A 2-week (...) , paliperidone extended-release improved symptoms earlier and to a greater degree in patients with recently exacerbated schizophrenia requiring hospitalization, with no unexpected tolerability findings.

2009 EvidenceUpdates Controlled trial quality: predicted high

702. Schizophrenia, substance abuse, and violent crime. Full Text available with Trip Pro

Schizophrenia, substance abuse, and violent crime. Persons with schizophrenia are thought to be at increased risk of committing violent crime 4 to 6 times the level of general population individuals without this disorder. However, risk estimates vary substantially across studies, and considerable uncertainty exists as to what mediates this elevated risk. Despite this uncertainty, current guidelines recommend that violence risk assessment should be conducted for all patients (...) with schizophrenia.To determine the risk of violent crime among patients diagnosed as having schizophrenia and the role of substance abuse in mediating this risk.Longitudinal designs were used to link data from nationwide Swedish registers of hospital admissions and criminal convictions in 1973-2006. Risk of violent crime in patients after diagnosis of schizophrenia (n = 8003) was compared with that among general population controls (n = 80 025). Potential confounders (age, sex, income, and marital and immigrant

2009 JAMA

703. Twenty-four hour care for schizophrenia. (Abstract)

Twenty-four hour care for schizophrenia. Despite modern treatment approaches and a focus on community care, there remains a group of people who cannot easily be discharged from psychiatric hospital directly into the community. Twenty-four hour residential rehabilitation (a 'ward-in-a-house') is one model of care that has evolved in association with psychiatric hospital closure programmes.To determine the effects of 24 hour residential rehabilitation compared with standard treatment within (...) a hospital setting.We searched the Cochrane Schizophrenia Group Trials Register (May 2002 and February 2004).We included all randomised or quasi-randomised trials that compared 24 hour residential rehabilitation with standard care for people with severe mental illness.Studies were reliably selected, quality assessed and data extracted. Data were excluded where more than 50% of participants in any group were lost to follow-up. For binary outcomes we calculated the relative risk and its 95% confidence

2009 Cochrane

704. A Meta-Analysis of Head-to-Head Comparisons of Second-Generation Antipsychotics in the Treatment of Schizophrenia Full Text available with Trip Pro

A Meta-Analysis of Head-to-Head Comparisons of Second-Generation Antipsychotics in the Treatment of Schizophrenia Whether there are differences in efficacy among second-generation antipsychotics in the treatment of schizophrenia is a matter of heated debate. The authors conducted a systematic review and meta-analysis of blinded studies comparing second-generation antipsychotics head-to-head.Searches of the Cochrane Schizophrenia Group's register (May 2007) and MEDLINE (September 2007) were (...) conducted for randomized, blinded studies comparing two or more of nine second-generation antipsychotics in the treatment of schizophrenia. All data were extracted by at least three reviewers independently. The primary outcome measure was change in total score on the Positive and Negative Syndrome Scale; secondary outcome measures were positive and negative symptom subscores and rate of dropout due to inefficacy. The results were combined in a meta-analysis. Various sensitivity analyses

2009 EvidenceUpdates

705. Clozapine versus typical neuroleptic medication for schizophrenia. (Abstract)

Clozapine versus typical neuroleptic medication for schizophrenia. Long-term drug treatment of schizophrenia with typical antipsychotics has limitations: 25 to 33% of patients have illnesses that are treatment-resistant. Clozapine is an antipsychotic drug, which is claimed to have superior efficacy and to cause fewer motor adverse effects than typical drugs for people with treatment-resistant illnesses. Clozapine carries a significant risk of serious blood disorders, which necessitates (...) mandatory weekly blood monitoring at least during the first months of treatment.To evaluate the effects of clozapine compared with typical antipsychotic drugs in people with schizophrenia.For the current update of this review (March 2006) we searched the Cochrane Schizophrenia Group Trials Register.All relevant randomised clinical trials (RCTs).We extracted data independently. For dichotomous data we calculated relative risks (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis

2009 Cochrane

706. Dance therapy for schizophrenia. (Abstract)

Dance therapy for schizophrenia. Dance therapy or dance movement therapy (DMT) is defined as 'the psychotherapeutic use of movement as a process which furthers the emotional, social, cognitive, and physical integration of the individual'. It may be of value for people with developmental, medical, social, physical or psychological impairments. Dance therapy can be practiced in mental health rehabilitation units, nursing homes, day care centres and incorporated into disease prevention and health (...) promotion programs.To evaluate the effects of dance therapy for people with schizophrenia or schizophrenia-like illnesses compared with standard care and other interventions.We searched the Cochrane Schizophrenia Group Trials Register (July 2007), inspected references of all identified studies (included and excluded), and contacted first authors for additional data.We included all randomised controlled trials (RCTs) comparing dance therapy and related approaches with standard care or other psychosocial

2009 Cochrane

707. Global pattern of experienced and anticipated discrimination against people with schizophrenia: a cross-sectional survey. (Abstract)

Global pattern of experienced and anticipated discrimination against people with schizophrenia: a cross-sectional survey. Many people with schizophrenia experience stigma caused by other people's knowledge, attitudes, and behaviour; this can lead to impoverishment, social marginalisation, and low quality of life. We aimed to describe the nature, direction, and severity of anticipated and experienced discrimination reported by people with schizophrenia.We did a cross-sectional survey in 27 (...) countries, in centres affiliated to the INDIGO Research Network, by use of face-to-face interviews with 732 participants with schizophrenia. Discrimination was measured with the newly validated discrimination and stigma scale (DISC), which produces three subscores: positive experienced discrimination; negative experienced discrimination; and anticipated discrimination.Negative discrimination was experienced by 344 (47%) of 729 participants in making or keeping friends, by 315 (43%) of 728 from family

2009 Lancet

708. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Full Text available with Trip Pro

Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Whether schizophrenia and bipolar disorder are the clinical outcomes of discrete or shared causative processes is much debated in psychiatry. We aimed to assess genetic and environmental contributions to liability for schizophrenia, bipolar disorder, and their comorbidity.We linked the multi-generation register, which contains information about all children and their parents (...) in Sweden, and the hospital discharge register, which includes all public psychiatric inpatient admissions in Sweden. We identified 9 009 202 unique individuals in more than 2 million nuclear families between 1973 and 2004. Risks for schizophrenia, bipolar disorder, and their comorbidity were assessed for biological and adoptive parents, offspring, full-siblings and half-siblings of probands with one of the diseases. We used a multivariate generalised linear mixed model for analysis of genetic

2009 Lancet

709. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. (Abstract)

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Because of the debate about whether second-generation antipsychotic drugs are better than first-generation antipsychotic drugs, we did a meta-analysis of randomised controlled trials to compare the effects of these two types of drugs in patients with schizophrenia.We compared nine second-generation antipsychotic drugs with first-generation drugs for overall efficacy (main outcome), positive

2009 Lancet

710. CBT for schizophrenia.

CBT for schizophrenia. September 2009 1 Evidence Briefing for Leeds Partnerships NHS Foundation Trust Cognitive behaviour therapy for schizophrenia  The NICE clinical guideline on schizophrenia 1 recommends that cognitive behaviour therapy (CBT) should be offered to all people with schizophrenia.  This recommendation is based primarily on evidence that CBT can reduce hospitalisation compared with standard care. A meta-analysis of randomised trials reported a 24% relative reduction (...) is limited but an economic model produced by the NICE Guideline Development Group indicated that provision of CBT is likely to result in cost savings overall.  The performance of Leeds Partnership Foundation Trust (LPFT) in providing CBT for service users with schizophrenia was rated ‘average’ by the Care Quality Commission in 2005/6 and 2007/8. An internal audit (April 2009) revealed that 17 out of 75 eligible service users had been offered CBT; 27 people were offered other psychosocial interventions

2009 Evidence briefings

711. Physical health monitoring for people with schizophrenia or other serious mental

Physical health monitoring for people with schizophrenia or other serious mental November 2009 1 Evidence Briefing for NHS Bradford and Airedale Physical health monitoring for people with schizophrenia or other serious mental illness ? The NICE clinical guideline on schizophrenia 1 recommends that GPs and other primary healthcare professionals should monitor the physical health of people with schizophrenia at least once a year. The assessment should focus on cardiovascular disease risk (...) assessment. ? Physical health reviews for people with schizophrenia and other serious mental illness form part of the National Quality and Outcomes Framework. ? An initial audit of 12 general practices in Bradford and Airedale revealed that while all practices had a case register of people with serious mental illness, none of the patient records examined reported a formal assessment of cardiovascular risk. Only 37% of patients had a record of cholesterol within the past 15 months. If these data

2009 Evidence briefings

712. Cognitive behaviour therapy for schizophrenia

Cognitive behaviour therapy for schizophrenia Cognitive behaviour therapy for schizophrenia Cognitive behaviour therapy for schizophrenia Centre for Reviews and Dissemination Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Centre for Reviews and Dissemination. Cognitive behaviour therapy for schizophrenia. University of York. Evidence (...) briefings. 2009 Authors' conclusions The NICE clinical guideline on schizophrenia1 recommends that cognitive behaviour therapy (CBT) should be offered to all people with schizophrenia. This recommendation is based primarily on evidence that CBT can reduce hospitalisation compared with standard care. A meta-analysis of randomised trials reported a 24% relative reduction in hospitalisation at follow-up (up to 18 months after treatment). Duration of hospitalisation was reduced by an average of 8 days

2009 Health Technology Assessment (HTA) Database.

713. Physical health monitoring for people with schizophrenia or other serious mental illness

Physical health monitoring for people with schizophrenia or other serious mental illness Physical health monitoring for people with schizophrenia or other serious mental illness Physical health monitoring for people with schizophrenia or other serious mental illness Centre for Reviews and Dissemination Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation Centre for Reviews and Dissemination. Physical health monitoring for people with schizophrenia or other serious mental illness . University of York. Evidence briefings. 2009 Authors' conclusions The NICE clinical guideline on schizophrenia recommends that GPs and other primary healthcare professionals should monitor the physical health of people with schizophrenia at least once a year. The assessment should focus on cardiovascular disease risk assessment. Physical health reviews

2009 Health Technology Assessment (HTA) Database.

714. Schizophrenia in either parent increases risk of infant mortality

Schizophrenia in either parent increases risk of infant mortality Schizophrenia in either parent increases risk of infant mortality | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Schizophrenia in either parent increases risk of infant mortality Article Text Aetiology Schizophrenia in either parent increases risk of infant mortality Statistics from Altmetric.com QUESTION Question: Is schizophrenia in either parent associated

2009 Evidence-Based Mental Health

715. Adjunctive transdermal oestradiol improves positive symptoms and general psychopathology in women with schizophrenia Full Text available with Trip Pro

Adjunctive transdermal oestradiol improves positive symptoms and general psychopathology in women with schizophrenia Adjunctive transdermal oestradiol improves positive symptoms and general psychopathology in women with schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Adjunctive transdermal oestradiol improves positive symptoms and general psychopathology in women with schizophrenia Article Text Therapeutics Adjunctive

2009 Evidence-Based Mental Health

716. Refractory schizophrenia: adding aripiprazole to clozapine reduces negative but not overall symptoms

Refractory schizophrenia: adding aripiprazole to clozapine reduces negative but not overall symptoms Refractory schizophrenia: adding aripiprazole to clozapine reduces negative but not overall symptoms | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Refractory schizophrenia: adding aripiprazole to clozapine reduces negative but not overall symptoms Article Text Therapeutics Refractory schizophrenia: adding aripiprazole to clozapine

2009 Evidence-Based Mental Health

717. Switching to aripiprazole from olanzapine leads to weight loss in overweight people with schizophrenia or schizoaffective disorder

Switching to aripiprazole from olanzapine leads to weight loss in overweight people with schizophrenia or schizoaffective disorder Switching to aripiprazole from olanzapine leads to weight loss in overweight people with schizophrenia or schizoaffective disorder | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see (...) our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Switching to aripiprazole from olanzapine leads to weight loss in overweight people with schizophrenia or schizoaffective

2009 Evidence-Based Mental Health

718. Early response to treatment predicts remission and recovery at 3 years in people with schizophrenia

Early response to treatment predicts remission and recovery at 3 years in people with schizophrenia Early response to treatment predicts remission and recovery at 3 years in people with schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Early response to treatment predicts remission and recovery at 3 years in people with schizophrenia Article Text Prognosis Early response to treatment predicts remission and recovery at 3

2009 Evidence-Based Mental Health

719. Clinical Practice Guideline for Schizophrenia and Incipient Psychotic Disorder

Clinical Practice Guideline for Schizophrenia and Incipient Psychotic Disorder Clinical Practice Guideline for Schizophrenia and Incipient Psychotic Disorder CLINICAL PRACTICE GUIDELINES IN THE NHS. MINISTRY OF HEALTHCARE AND CONSUMER AFFAIRS CLINICAL PRACTICE GUIDELINES FOR SCHIZOPHENIA AND INCIPIENT PSYCHOTIC DISORDER 2 Clinical Practice Guideline for Schizophrenia and Incipient Psychotic Disorder Clinical Practice Guidelines in the NHS Number 2006/05-2 CLINICAL PRACTICE GUIDELINES IN THE NHS (...) the Carlos III Institute of Health, an autonomous organism of the Ministry of Health and Consumer Affairs (MSC), and the Catalan Agency for Health Technology Assessment and Research, within the framework of collaboration forecasted in the Quality Plan for the National Health System. How to cite this document: Working Group of the Clinical Practice Guideline for Schizophrenia and Incipient Psychotic Disorder. Mental Health Forum, coordination. Clinical Practice Guideline for Schizophrenia and Incipient

2009 GuiaSalud

720. Quetiapine prolonged-release tablets (Seroquel XL®) for the treatment of schizophrenia in adults

Quetiapine prolonged-release tablets (Seroquel XL®) for the treatment of schizophrenia in adults Quetiapine prolonged-release tablets (Seroquel XL®) for the treatment of schizophrenia in adults Quetiapine prolonged-release tablets (Seroquel XL®) for the treatment of schizophrenia in adults All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation All Wales Medicines Strategy Group (AWMSG). Quetiapine prolonged-release tablets (Seroquel XL®) for the treatment of schizophrenia in adults. Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 1509. 2009 Authors' conclusions Quetiapine prolonged-release tablets (Seroquel XL®) are recommended as an option for use within NHS Wales for the treatment of schizophrenia

2009 Health Technology Assessment (HTA) Database.